Toll Free: 1-888-928-9744

Pneumocystis Infection - Pipeline Review, H2 2014

Published: Dec, 2014 | Pages: 29 | Publisher: Global Markets Direct
Industry: Healthcare | Report Format: Electronic (PDF)

Pneumocystis Infection - Pipeline Review, H2 2014

Summary

Global Markets Direct's, 'Pneumocystis Infection - Pipeline Review, H2 2014', provides an overview of the Pneumocystis Infection's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Pneumocystis Infection, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Pneumocystis Infection and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Pneumocystis Infection
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in the therapeutics development for Pneumocystis Infection and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects 
- A review of the Pneumocystis Infection products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Pneumocystis Infection pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Pneumocystis Infection
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Pneumocystis Infection pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
 Table of Contents
Table of Contents 2
List of Tables 3
List of Figures 3
Introduction 4
Global Markets Direct Report Coverage 4
Pneumocystis Infection Overview 5
Therapeutics Development 6
Pipeline Products for Pneumocystis Infection - Overview 6
Pipeline Products for Pneumocystis Infection - Comparative Analysis 7
Pneumocystis Infection - Therapeutics under Development by Companies 8
Pneumocystis Infection - Therapeutics under Investigation by Universities/Institutes 9
Pneumocystis Infection - Pipeline Products Glance 10
Early Stage Products 10
Pneumocystis Infection - Products under Development by Companies 11
Pneumocystis Infection - Products under Investigation by Universities/Institutes 12
Pneumocystis Infection - Companies Involved in Therapeutics Development 13
BioDiem Ltd 13
Pneumocystis Infection - Therapeutics Assessment 14
Assessment by Monotherapy Products 14
Assessment by Route of Administration 15
Assessment by Molecule Type 16
Drug Profiles 18
BDM-I - Drug Profile 18
Product Description 18
Mechanism of Action 18
R&D Progress 18
Monoclonal Antibody for Pneumocystis Infection - Drug Profile 19
Product Description 19
Mechanism of Action 19
R&D Progress 19
MVX-504 - Drug Profile 20
Product Description 20
Mechanism of Action 20
R&D Progress 20
MVX-505 - Drug Profile 22
Product Description 22
Mechanism of Action 22
R&D Progress 22
pneumocystis vaccine - Drug Profile 23
Product Description 23
Mechanism of Action 23
R&D Progress 23
Pneumocystis Infection - Recent Pipeline Updates 24
Pneumocystis Infection - Discontinued Products 26
Pneumocystis Infection - Product Development Milestones 27
Featured News & Press Releases 27
May 10, 2013: BioDiem's BDM-I Progresses To Preclinical Animal Studies In NIH Research Program As Fungal Infection Treatment 27
Jun 04, 2012: MiniVax's Pneumocystis Vaccine Candidate Induces Significant anti-Pneumocystis Antibody Responses and Reduced Fungal Load 27
Appendix 28
Methodology 28
Coverage 28
Secondary Research 28
Primary Research 28
Expert Panel Validation 28
Contact Us 29
Disclaimer 29
List of Tables
Number of Products under Development for Pneumocystis Infection, H2 2014 6
Number of Products under Development for Pneumocystis Infection - Comparative Analysis, H2 2014 7
Number of Products under Development by Companies, H2 2014 8
Number of Products under Investigation by Universities/Institutes, H2 2014 9
Comparative Analysis by Early Stage Development, H2 2014 10
Products under Development by Companies, H2 2014 11
Products under Investigation by Universities/Institutes, H2 2014 12
Pneumocystis Infection - Pipeline by BioDiem Ltd, H2 2014 13
Assessment by Monotherapy Products, H2 2014 14
Number of Products by Stage and Route of Administration, H2 2014 15
Number of Products by Stage and Molecule Type, H2 2014 17
Pneumocystis Infection Therapeutics - Recent Pipeline Updates, H2 2014 24
Pneumocystis Infection - Discontinued Products, H2 2014 26 



                                

To request a free sample copy of this report, please complete the form below.

We never share your personal data. Privacy policy
Interested in this report? Get your FREE sample now! Get a Free Sample
Choose License Type
Single User - US $2000
Multi User - US $4000
Hexareeasearch Know

Did you know?

Research Assistance

Phone: 1-415-349-0054

Toll Free: 1-888-928-9744

Email: [email protected]

Why to buy from us

Custom research service

Speak to the report author to design an exclusive study to serve your research needs.

Information security

Your personal and confidential information is safe and secure.

verify